Depression in parkinson's disease: Identification and management

Pharmacotherapy

Volumn 33, Issue 9, 2013, Pages 972-983

  Chen, Jack J ^a   Marsh, Laura ^b,c  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antidepressants; Depression; Mental health services; Mood; Neurology; Parkinson's disease; Pharmacotherapy; Psychiatry; Serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ATOMOXETINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEVODOPA; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADD ON THERAPY; AGITATION; AGRANULOCYTOSIS; ANXIETY DISORDER; BECK DEPRESSION INVENTORY; BEDTIME DOSAGE; BRAIN DEPTH STIMULATION; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONSTIPATION; DELIRIUM; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DSM-IV; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; HALLUCINATION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; LIVER DISEASE; LOW DRUG DOSE; MAJOR DEPRESSION; MEDICAL DECISION MAKING; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; PERSONALIZED MEDICINE; PRESCRIPTION; PSYCHOSIS; QUALITY OF LIFE; RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER; REVIEW; RISK BENEFIT ANALYSIS; SCREENING TEST; SEDATION; SEIZURE; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUBTHALAMIC NUCLEUS; TREATMENT RESPONSE; TREMOR; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIDEPRESSANTS; DEPRESSION; MENTAL HEALTH SERVICES; MOOD; NEUROLOGY; PARKINSON'S DISEASE; PHARMACOTHERAPY; PSYCHIATRY; SEROTONIN REUPTAKE INHIBITORS; TRICYCLIC ANTIDEPRESSANTS;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; PARKINSON DISEASE; PSYCHOTHERAPY;

EID: 84885356652     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1314     Document Type: Review

References (76)

1. Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002;17:60-7
2. Hughes TA, Ross HF, Mindham RHS, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-23
3. Marsh L, McDonald WM, Cummings J, Ravina B; NINDS/ NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21:148-58
4. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003;16:178-83
5. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-7
6. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:187-96
7. Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord 2003;10:23-8
8. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993;34:465-70
9. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990;3:3-9
10. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003;18:414-8
11. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011;68:165-71
12. Tan SK, Hartung H, Sharp T, Temel Y. Serotonin-dependent depression in Parkinson's disease: a role for the subthalmic nucleus? Neuropharmacology 2011;61:387-99
13. Benoit M, Robert PH. Imaging correlates of apathy and depression in Parkinson's disease. J Neurol Sci 2011;310:58-60
14. Murai T, Muller U, Werheid K, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:222-8
15. Cheng EM, Siderowf A, Swarztrauber K, Eisa M, Lee M, Vickrey BG. Development of quality of care indicators for Parkinson's disease. Mov Disord 2004;19:136-50
16. Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med 2006;166:2314-21
17. American Psychiatric Association. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th ed. Text Revised. Washington, DC: American Psychiatric Association Press, 2000
18. Starkstein SE, Preziosi TJ, Forrester AW, Robinson RG. Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:869-73
19. Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:765-76
20. Williams JR, Hirsch ES, Anderson K, et al. A comparison of nine scales to detect depression in Parkinson disease: which scale to use? Neurology 2012;78:998-1006
21. Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 2006;14:169-75
22. Scheinthal SM, Steer RA, Giffin L, Beck AT. Evaluating geriatric medical outpatients with the Beck Depression Inventory- Fastscreen for medical patients. Aging Ment Health 2001;5:143-8
23. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24:221-7
24. Pintor L, Bailles E, Valldeoriola F, Tolosa E, Marti MJ, de Pablo J. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gen Hosp Psychiatry 2006;28:59-64
25. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300-4
26. Takahashi H, Kamata M, Yoshida K, Higuchi H, Shimizu T. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:351-3
27. Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion [in Dutch]. Ned Tijdschr Geneeskd 2000;144:2157-9
28. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002;25:21-4
29. Aarsland D, Larsen JP, Lim NG, Wermuth L, Bech P. A2- adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson's disease and depression. Nord J Psychiatry 2000;54:411-5
30. Rihmer Z, Satori M, Pestality P. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract 2000;4:123-5
31. Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 2006;18:377-83
32. Montastruc JL, Fabre N, Blin O, Senard JM, Rascol O, Rascol A. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord 1995;10:355-7
33. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55:1216-8
34. Tesei S, Antoini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15:986-9
35. Wittgens W, Donath O, Trenckmann U. Treatment of depressive syndromes in Parkinson's disease (P.D.) with paroxetine. Mov Disord 1997;12(Suppl 1):128 [Abstract]
36. Bayulkem K, Torun F. Effectiveness of sertraline in treatment of depression with Parkinson's disease. Mov Disord 2002;17 (Suppl 5):S74 [Abstract]
37. Bayulkem K, Torun F. Therapeutic efficiency of venlafaxine in depressive patients with Parkinson's disease. Mov Disord 2002;7(Suppl 5):S75 [Abstract]
38. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12:756-9
39. Meara RJ, Bhowmick BK, Hobson JP. An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson's disease. J Serotonin Res 1996;4:243-9
40. Mandell AJ, Markham C, Fowler W. Parkinson's syndrome, depression and imipramine: a preliminary report. Calif Med 1961;95:12-4
41. Strauss H. Office treatment of depressive states with a new drug (imipramine). NY State J Med 1959;59:2906-10
42. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord 2006;21:1119-22
43. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1171-4
44. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson disease?: a pilot randomized trial. J Clin Psychopharmacol 2003;23:509-13
45. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FRJ. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003;18:552-4
46. Serrano-Duenas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease [in Spanish]. Rev Neurol 2002;35:1010-4
47. Wermuth L, Sorensen PS, Timm B, et al. Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial. Nordic J Psychiatry 1998;52:163-9
48. Rabey JM, Orlov E, Korczyn AD. Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease. Neurology 1996;46:A374 [Abstract]
49. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23:850-7
50. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-92
51. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-36
52. Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurol Sci 2008;29:391-5
53. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-7
54. Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurol Scand 1969;45:109-13
55. Strang RR. Imipramine in treatment of Parkinson's disease: a double-blind placebo study. BMJ 1965;2:33-4
56. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pederson HE. Antidepressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980;62:210-9
57. Weiser R, Hernandez-Rojas J, Flores J, Gallardo M, Garcia M, Grau M. Efficacy, tolerability and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson's disease. Mov Disord 2004;19(Suppl 9):S205 [Abstract]
58. Steur EN, Ballering LA. Moclobemide and selegiline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:547
59. Bonuccelli U, Meco G, Fabbrini G, et al. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opin Pharmacother 2012;13:2269-80
60. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 2010;10:49
61. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S42-80
62. Richard IH,. Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Neurology 1997;49:1168-70
63. Facts and Comparisons. Anon Drug Facts and Comparisons . St. Louis: Facts and Comparisons, 2013
64. Linder MW,. Keck PE Jr. Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1073-84
65. Mahmoud F, Tampi RR. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatr Pharmacother 2011;9:405-12
66. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999;53:1154
67. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75:448-55
68. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406
69. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005;17:214-20
70. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573-80
71. Rektorova I, Balaz M, Svatova J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson's disease: a prospective multicenter study. Clin Neuropharmacol 2008;31:261-6
72. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95
73. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-74
74. Armento MEA, Stanley MA, Marsh L, Kunik ME, York MK, Calleo JS. Cognitive behavioral therapy (CBT) for depression and anxiety in Parkinson's disease: a clinical review. J Parkinson's Dis 2012;2:135-51
75. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord 2010;25:2311-7
76. Dereli EE, Yaliman A. Comparison of the effects of a physiotherapist- supervised exercise programme and a self-supervised exercise programme on quality of life in patients with Parkinson's disease. Clin Rehabil 2010;24:352-62